There is a lack of low toxicity, specific anticancer therapies and in many cancer types there are limited effective treatments. Enhancer RNAs are noncoding RNA transcripts transcribed from enhancer regions. Increasing evidence of the function of eRNA in gene regulation suggests the possibility of eRNA involvement in cancer development. This report examines literature on enhancer RNA as a potent component in transcription control specifically in cancer development. Therefore, I conducted a systematic literature review to further clarify the involvement of eRNAs in cancer. There is strong evidence of eRNA upregulating oncogenes. For instance, the eRNA (CCAT1) upregulates the oncogene MYC in colorectal cancer. Other eRNAs were also found to be required for p53-dependent cell-cycle arrest and tumour inhibition. A study showed the interplay of a long noncoding RNA with eRNAs in p53-regulated enhancers, while another showed p53-bound enhancer regions transcribing an eRNA which mediates G1 arrest, DNA repair, and tumorigenesis through its interaction with the (BRCA2) gene. Finally, a study across numerous cancer patient samples revealed a cancer/lineage specificity of eRNAs and explored the clinical feasibility of eRNA-targeted therapy. These studies demonstrate how eRNAs can be a link in cancer signalling pathways both as a regulator of oncogenes and tumour suppressor genes, as well as suggest a promising future of eRNA-targeted cancer therapy.
Identifer | oai:union.ndltd.org:UPSALLA1/oai:DiVA.org:uu-526734 |
Date | January 2024 |
Creators | Seek, Abd Aljabbar |
Publisher | Uppsala universitet, Institutionen för farmaceutisk biovetenskap |
Source Sets | DiVA Archive at Upsalla University |
Language | English |
Detected Language | English |
Type | Student thesis, info:eu-repo/semantics/bachelorThesis, text |
Format | application/pdf |
Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0133 seconds